Cited by 590Colorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy

Becht, Etienne, de Reyniès, Aurélien, Giraldo, Nicolas A., Pilati, Camilla, Buttard, Bénédicte, Lacroix, Laetitia, Selves, Janick, Sautès-Fridman, Catherine +2 more·2016·Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: The tumor microenvironment is formed by many distinct and interacting cell populations, and its composition may predict patients' prognosis and response to therapies. Colorectal cancer is a heterogeneous disease in which immune classifications and four consensus molecular subgroups (CMS) have been described. Our aim was to integrate the composition of the tumor microenvironment with the consensus molecular classification of colorectal cancer. Experimental Design: We retrospectively analyzed the composition and the functional orientation of the immune, fibroblastic, and angiogenic microenvironment of 1,388 colorectal cancer tumors from three independent cohorts using transcriptomics. We validated our findings using immunohistochemistry. Results: We report that colorectal cancer molecular subgroups and microenvironmental signatures are highly correlated. Out of the four molecular subgroups, two highly express immune-specific genes. The good-prognosis microsatellite instable–enriched subgroup (CMS1) is characterized by overexpression of genes specific to cytotoxic lymphocytes. In contrast, the poor-prognosis mesenchymal subgroup (CMS4) expresses markers of lymphocytes and of cells of monocytic origin. The mesenchymal subgroup also displays an angiogenic, inflammatory, and immunosuppressive signature, a coordinated pattern that we also found in breast (n = 254), ovarian (n = 97), lung (n = 80), and kidney (n = 143) cancers. Pathologic examination revealed that the mesenchymal subtype is characterized by a high density of fibroblasts that likely produce the chemokines and cytokines that favor tumor-associated inflammation and support angiogenesis, resulting in a poor prognosis. In contrast, the canonical (CMS2) and metabolic (CMS3) subtypes with intermediate prognosis exhibit low immune and inflammatory signatures. Conclusions: The distinct immune orientations of the colorectal cancer molecular subtypes pave the way for tailored immunotherapies. Clin Cancer Res; 22(16); 4057–66. ©2016 AACR.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-2879

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H.
Affiliations
  • 1INSERM UMR_S 1138, Cancer, Immune Control and Escape, Cordeliers Research Centre, Paris, France.
  • 4Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.
  • Inserm (FR)
  • 6Centre de Recherche en Cancérologie de Toulouse, Unité Mixte de Recherche, 1037 INSERM - Université Toulouse III, Toulouse, France.
  • 2Université Paris Descartes, Paris, France.
Corresponding author
Fridman, Wolf Herman
Venue
Clinical Cancer Research
Published
2016-08-14
Volume
22
Issue
16
Pages
4057-4066
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2310046094
Cited by
590
References
43
Citations by year
2026: 28 · 2025: 30 · 2024: 52 · 2023: 67 · 2022: 71 · 2021: 99 · 2020: 68 · 2019: 70 · 2018: 49 · 2017: 41 · 2016: 11
FWCI
30.57
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Agence Nationale de la Recherche (ANR-10-LABX-0015)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
colorectal cancer, consensus molecular subtypes, tumor microenvironment, immune cell composition, stromal fibroblasts, tumor-associated macrophages, angiogenesis, tumor-infiltrating lymphocytes, mesenchymal subtype, microsatellite instability, immunotherapy response, cancer immunotherapy, transcriptomics, cross-cancer analysis
MeSH terms
Cancer-Associated Fibroblasts, Humans, Immunotherapy, Neovascularization, Pathologic, Biomarkers, Tumor, Colorectal Neoplasms, Cluster Analysis, Stromal Cells, Gene Expression Profiling, Cell Line, Tumor, Precision Medicine, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review